Goldman Sachs expects Nvidia ’beat and raise,’ lifts price target to $240
DUBLIN - Morgan Stanley & Co. International plc disclosed Tuesday its dealings in Avadel Pharmaceuticals plc (NASDAQ:AVDL) securities as required under Irish takeover regulations.
According to a regulatory filing with the Irish Takeover Panel, Morgan Stanley, acting as an exempt principal trader with recognized intermediary status, purchased and subsequently sold 1,310 ordinary shares of Avadel Pharmaceuticals on Monday, October 27, 2025.
The transactions were executed at prices ranging between $18.55 and $18.555 per share, as detailed in the disclosure made under Rule 38.5(a) of the Irish Takeover Panel Act.
The filing identifies Morgan Stanley as connected to Avadel Pharmaceuticals in relation to an unspecified offer or potential offer. No cash-settled derivative transactions, stock-settled derivative transactions, or other dealings were reported in the disclosure.
The company also confirmed there were no indemnity arrangements or agreements relating to options or derivatives between the parties involved.
This disclosure was made in compliance with Irish takeover regulations that require connected exempt principal traders to report dealings in relevant securities during an offer period.
The information was provided through a Regulatory Information Service, based on a company press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.